May 2009
Signum presents 2 posters highlighting the efficacy in safety of GPMs at the 69th annual Society for Investigative Dermatology (SID) in Montreal. Read More
May 2009
Dr. Richard D. Granstein presents at the 69th annual Society of Investigative Dermatology that GPMs are effective in reducing key inflammatory mediators in a cell based that may be useful for the identification of potential new therapeutics for rosacea. Read More
March 2009
Dr. Zoe Draelos presents Signum’s GPM Technology as a new class of topical anti-inflamatories at the American Academy of Dermatology (AAD) meeting in San Francisco. Read More
Interested in a job at Signum? Visit our job postings section for a listing of our open positions.
In collaboration with the University of Pennsylvania we are investigating the effects of GPMs on UVB-induced inflammation.
Signum has been awarded a $1.6 million SBIR Phase II grant by the NIAID to continue the development of its topical STM anti-inflammatory technology for the treatment of skin disease.
In collaboration with the University of Medicine and Dentistry of New Jersey, we are investigating the effects of PPM compounds on α-synuclein phosphorylation in mouse models of Parkinson’s Disease.